Reference interval and the role of plasma oligomeric beta amyloid in screening of risk groups for cognitive dysfunction at health checkups

Reference interval and the role of plasma oligomeric beta amyloid in screening of risk groups for cognitive dysfunction at health checkups

Background: Alzheimer's disease (AD) has a prolonged preclinical stage characterized by cognitive dysfunction. Simple, reliable, and noninvasive biomarkers reflecting the pathogenesis of AD are needed for screening cognitive dysfunction in primary health care. The aims of this study were to det...

Full description

Bibliographic Details
Main Authors: Cho, H.-I (Author), Cho, S. (Author), Hwang, I. (Author), Nah, E.-H (Author), Noh, D. (Author), Park, H. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2021
Subjects:
adult
aged
Aged
Aged, 80 and over
Alzheimer disease
Alzheimer's disease
amyloid beta protein
Amyloid beta-Peptides
Article
biological marker
Biomarkers
blood
chemistry
cognition
cognitive assessment
cognitive defect
Cognitive Dysfunction
confidence interval
controlled study
female
Female
Healthy Volunteers
human
Humans
major clinical study
male
Male
mass screening
middle aged
Middle Aged
Mini Mental State Examination
multimer detection system
normal human
oligomer
oligomeric amyloid-β
Prospective Studies
prospective study
protein analysis
protein blood level
reference interval
reference value
Reference Values
Republic of Korea
risk assessment
risk factor
Risk Factors
scoring system
South Korea
very elderly
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items